The Pharmacogenetics and Pharmacodynamics of Clopidogrel Response

Geiger, 1999, Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel, Arterioscler Thromb Vasc Biol, 19, 2007, 10.1161/01.ATV.19.8.2007 Serebruany, 2005, Variability in platelet responsiveness to clopidogrel among 544 individuals, J Am Coll Cardiol, 45, 246, 10.1016/j.jacc.2004.09.067 Gurbel, 2003, Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity, Circulation, 107, 2908, 10.1161/01.CIR.0000072771.11429.83 Muller, 2003, Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement, Thromb Haemost, 89, 783, 10.1055/s-0037-1613462 Clarke, 2003, The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin, Drug Metab Dispos, 31, 53, 10.1124/dmd.31.1.53 Brandt, 2007, Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel, J Thromb Haemost, 5, 2429, 10.1111/j.1538-7836.2007.02775.x Suh, 2006, Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel, CMAJ, 174, 1715, 10.1503/cmaj.060664 Farid, 2007, Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently, Clin Pharmacol Ther, 81, 735, 10.1038/sj.clpt.6100139 Hulot, 2006, Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects, Blood, 108, 2244, 10.1182/blood-2006-04-013052 Fontana, 2007, Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects, J Thromb Haemost, 5, 2153, 10.1111/j.1538-7836.2007.02722.x Lau, 2004, Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance, Circulation, 109, 166, 10.1161/01.CIR.0000112378.09325.F9 Wang, 2005, Ile118Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering efficacy of simvastatin in Chinese hyperlipidemic patients, Eur J Clin Pharmacol, 60, 843, 10.1007/s00228-004-0848-7 Hesselink, 2003, Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus, Clin Pharmacol Ther, 74, 245, 10.1016/S0009-9236(03)00168-1 Hesselink, 2004, Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes, Clin Pharmacol Ther, 76, 545, 10.1016/j.clpt.2004.08.022 van Schaik, 2001, The CYP3A4*3 allele: is it really rare?, Clin Chem, 47, 1104, 10.1093/clinchem/47.6.1104 van Schaik, 2000, CYP3A4-V polymorphism detection by PCR-restriction fragment length polymorphism analysis and its allelic frequency among 199 Dutch Caucasians, Clin Chem, 46, 1834, 10.1093/clinchem/46.11.1834 Angiolillo, 2006, Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel, Arterioscler Thromb Vasc Biol, 26, 1895, 10.1161/01.ATV.0000223867.25324.1a Kuehl, 2001, Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression, Nat Genet, 27, 383, 10.1038/86882 Sim, 2006, A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants, Clin Pharmacol Ther, 79, 103, 10.1016/j.clpt.2005.10.002 Brandt, 2007, Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel, J Thromb Haemost, 5, 2429, 10.1111/j.1538-7836.2007.02775.x von Beckerath, 2005, Circulation, 112, 2946, 10.1161/CIRCULATIONAHA.105.559088 Taubert, 2006, Impact of P-glycoprotein on clopidogrel absorption, Clin Pharmacol Ther, 80, 486, 10.1016/j.clpt.2006.07.007 Fontana, 2003, Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects, Circulation, 108, 989, 10.1161/01.CIR.0000085073.69189.88 Fontana, 2003, P2Y12 H2 haplotype is associated with peripheral arterial disease: a case-control study, Circulation, 108, 2971, 10.1161/01.CIR.0000106904.80795.35 von Beckerath, 2005, P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose, Blood Coagul Fibrinolysis, 16, 199, 10.1097/01.mbc.0000164429.21040.0a Tang, 2006, Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol, J Pharmacol Exp Ther, 319, 1467, 10.1124/jpet.106.110577 Marsh, 2004, Pharmacogenomic assessment of carboxylesterases 1 and 2, Genomics, 84, 661, 10.1016/j.ygeno.2004.07.008 Gladding, 2008, The antiplatelet effect of higher loading and maintenance dose regimens of clopidogrel: the PRINC (Plavix Response in Coronary Intervention) trial, J Am Coll Cardiol Intv, 1, 612, 10.1016/j.jcin.2008.09.005 Luo, 2006, Genetic polymorphism of cytochrome P450 2C19 in Mexican Americans: a cross-ethnic comparative study, Clin Pharmacol Ther, 80, 33, 10.1016/j.clpt.2006.03.003 Kahn, 2007, Race in a bottle, Sci Am, 297, 40, 10.1038/scientificamerican0807-40 Gilard, 2006, Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin, J Thromb Haemost, 4, 2508, 10.1111/j.1538-7836.2006.02162.x Gilard, 2008, Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study, J Am Coll Cardiol, 51, 256, 10.1016/j.jacc.2007.06.064 Malek, 2008, Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel, Circ J, 72, 1165, 10.1253/circj.72.1165 Patti, 2005, Circulation, 111, 2099, 10.1161/01.CIR.0000161383.06692.D4 Trenk, 2008, Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents, J Am Coll Cardiol, 51, 1925, 10.1016/j.jacc.2007.12.056 Romkes, 1991, Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily, Biochemistry, 30, 3247, 10.1021/bi00227a012